Human IGF-II (Receptor Grade)
- Known as:
- Human IGF-II (Receptor Grade)
- Catalog number:
- FM001
- Product Quantity:
- 1 mg
- Category:
- -
- Supplier:
- Gropep Bioreagents
- Gene target:
- Human IGF- (Receptor Grade)
Ask about this productRelated genes to: Human IGF-II (Receptor Grade)
- Gene:
- AIRN NIH gene
- Name:
- antisense of IGF2R non-protein coding RNA
- Previous symbol:
- -
- Synonyms:
- AIR, NCRNA00088, IGF2RAS, IGF2R-AS1
- Chromosome:
- 6q25.3
- Locus Type:
- RNA, long non-coding
- Date approved:
- 2008-11-25
- Date modifiied:
- 2018-08-15
- Gene:
- CCN1 NIH gene
- Name:
- cellular communication network factor 1
- Previous symbol:
- IGFBP10, CYR61
- Synonyms:
- GIG1
- Chromosome:
- 1p22.3
- Locus Type:
- gene with protein product
- Date approved:
- 1998-03-02
- Date modifiied:
- 2018-10-11
- Gene:
- CCN2 NIH gene
- Name:
- cellular communication network factor 2
- Previous symbol:
- CTGF
- Synonyms:
- IGFBP8
- Chromosome:
- 6q23.2
- Locus Type:
- gene with protein product
- Date approved:
- 1992-12-01
- Date modifiied:
- 2018-10-11
- Gene:
- CCN3 NIH gene
- Name:
- cellular communication network factor 3
- Previous symbol:
- NOV
- Synonyms:
- IGFBP9
- Chromosome:
- 8q24.12
- Locus Type:
- gene with protein product
- Date approved:
- 1993-11-05
- Date modifiied:
- 2018-10-11
- Gene:
- FCGR2A NIH gene
- Name:
- Fc fragment of IgG receptor IIa
- Previous symbol:
- FCG2, FCGR2A1, FCGR2
- Synonyms:
- CD32, CD32A, IGFR2, CDw32
- Chromosome:
- 1q23.3
- Locus Type:
- gene with protein product
- Date approved:
- 1988-11-30
- Date modifiied:
- 2019-04-23
Related products to: Human IGF-II (Receptor Grade)
Related articles to: Human IGF-II (Receptor Grade)
- Somatotropic gene expression has been altered by genetic selection, and developmental changes in insulin-like growth factor (IGF) and IGF binding protein (IGFBP) expression may contribute to rapid growth and muscle accretion in commercial broilers. The objective of this study was to evaluate changes in somatotropic axis activity between embryonic day (e) 12 and post-hatch day (d) 21. Liver and breast muscle (pectoralis major) were collected to measure gene expression, and blood was collected post-hatch to measure circulating IGFs. Liver IGF1 rose rapidly post-hatch and, in muscle, IGF1 exhibited a dynamic expression pattern. Levels decreased from e14 to e20, returned to e14 levels at d3, decreased again at d10, and stayed low thereafter. In both tissues, mRNA levels of several IGFBPs changed between embryogenesis and post-hatch. Liver IGFBP2 increased between e12 and e20, returned to e12 levels on d1, and remained low. Conversely, liver IGFBP4 expression was greater post-hatch than during embryogenesis. Expression of select IGFBPs was depressed in liver during the peri-hatch period. Liver IGFBP1, IGFBP3, IGFBP5, and IGFBP7 mRNA levels all decreased around this time and returned to embryonic levels by d3. In breast muscle, expression of both IGFBP2 and IGFBP4 was reduced after hatch. Circulating insulin-like growth factor IGF1 and IGF2 levels did not change between hatch and d21. These data suggest that post-hatch IGF effects are likely modulated by target tissue IGFR1 and IGFBP expression rather than changes in circulating hormone levels, with promotion or restriction of IGF-receptor binding regulating growth. Downregulation of several IGFBPs synthesized in the liver may facilitate the metabolic transition from utilizing yolk lipids to dietary carbohydrates. Several IGFBPs produced in breast muscle appear to have growth-promotive effects during embryogenesis but restrict growth of this tissue after hatch, as their post-hatch downregulation could facilitate local IGF signaling. These developmental gene expression patterns suggest that somatotropic hormonal signaling regulating growth and muscle accretion might be controlled through differential actions of IGFBPs and provide a basis for future functional studies. - Source: PubMed
Publication date: 2024/08/05
Vaccaro Lauren AHerring KyleWilson AbigailEngland EmmaSmith Addison LEllestad Laura E - Hybridization and polyploid breeding are the main approaches used to obtain new aquaculture varieties. Allotriploid crucian carp (3n) with rapid growth performance was generated by mating red crucian carp (RCC) with allotetraploids (4n). Fish growth is controlled by the growth hormone (GH)/insulin-like growth factor (IGF) axis. In the present study, we examined the expression characteristics of GH/IGF axis genes in hybrids F, 4n, 3n, RCC and common carp (CC). The results showed that GHRa, GHRb, IGF1, IGF2, and IGF-1Ra were highly expressed in 3n compared with RCC and CC, whereas IGF3 was undetectable in the liver in RCC, CC and 3n. GHRa and GHRb had low expression in the 4n group. In hybrid F, GHRa expression was low, whereas GHRb was highly expressed compared to the levels in RCC and CC. Moreover, in hybrid F, the expression of IGF3 was higher, and the expression of IGF1 and IGF2 was lower than that in the RCC and CC, whereas the expression of IGF-1Ra was similar to that in RCC and CC. For the IGFBP genes, IGFBP1 had higher expression in 3n compared than that in RCC and CC, while other IGFBP genes were not high expressed in 3n. Among the genes detected in this study, 11 genes were nonadditively expressed in 3n, with 5 genes in the transgressive upregulation model. We proposed that the 11 nonadditive expression of GH/IGF axis genes is related to growth heterosis in 3n. This evidence provides new insights into hybridization and polyploid breeding from the perspective of hormone regulation. - Source: PubMed
Publication date: 2024/03/26
Qing WeilingRen BingxinLou ChenyiZhong HuanZhou YiLiu Shaojun - Goats are of significant economic importance, yet our knowledge of the molecular pathways involved in their pregnancy remains limited. This study aims to investigate the role of IGFs in uterine and ovarian cellular events during pregnancy in goats. Forty-two Hair Goats were examined, including four pregnancy groups representing embryo-positive (G1, n=7), early (G2, n=7), mid (G3, n=7), and late pregnancy (G4, n=7), as well as two luteal stage groups representing early (G5, n=7) and late (G6, n=7) phases. Uterine and ovarian tissues were collected, and RT-qPCR and immunohistochemistry were performed to evaluate IGF expression. The results showed that IGF1 and IGF2 expressions were significantly higher in G1 than in other pregnancy and control groups (p < 0.05). Additionally, IGFBP1 expression was higher in G2 than in G1 and G4 (p < 0.05), and IGFBP3 expression was higher in G4 than in any other pregnancy stage (p < 0.05). However, no statistically significant differences were observed in the expression levels of IGFBP4 and IGFBP6 between any of the groups. Finally, IGFBP5 expression was significantly higher in G1, G3, and G4 compared to G2 (p < 0.05). Overall, the dynamic changes observed in the expression of the IGF gene family during different stages of pregnancy highlight the crucial role of IGFs in regulating pregnancy in goats. - Source: PubMed
Publication date: 2023/09/19
Ağaoğlu Özgecan KorkmazAğaoğlu Ali RehaÖzmen ÖzlemTurgut Ali OsmanSaatci Mustafa - Intrauterine growth impairment is associated with long-term metabolic changes (perinatal programming). We recently demonstrated that antenatal betamethasone (BET) decreased head circumference in term born females. Since glucose is the main energy source for fetal growth, BET-induced changes in maternal glucose homeostasis, a reduced transplacental glucose transfer or an altered fetal glucose utilization may be linked with the observed growth impairment. - Source: PubMed
Publication date: 2023/07/27
Hardt Anne-KatrinBraun Tavares FranziskaEhrlich LoreenHenrich WolfgangPlagemann AndreasBraun Thorsten - While fetal growth is dependent on many factors, optimal placental function is a prerequisite for a normal pregnancy outcome. The majority of fetal growth-restricted (FGR) pregnancies result from placental insufficiency (PI). The insulin-like growth factors (IGF1 and IGF2) stimulate fetal growth and placental development and function. Previously, we demonstrated that in vivo RNA interference (RNAi) of the placental hormone, chorionic somatomammotropin (CSH), resulted in two phenotypes. One phenotype exhibits significant placental and fetal growth restriction (PI-FGR), impaired placental nutrient transport, and significant reductions in umbilical insulin and IGF1. The other phenotype does not exhibit statistically significant changes in placental or fetal growth (non-FGR). It was our objective to further characterize these two phenotypes by determining the impact of CSH RNAi on the placental (maternal caruncle and fetal cotyledon) expression of the IGF axis. The trophectoderm of hatched blastocysts (9 days of gestation, dGA) were infected with a lentivirus expressing either a non-targeting sequence (NTS RNAi) control or CSH-specific shRNA (CSH RNAi) prior to embryo transfer into synchronized recipient ewes. At ≈125 dGA, pregnancies were fitted with vascular catheters to undergo steady-state metabolic studies. Nutrient uptakes were determined, and tissues were harvested at necropsy. In both CSH RNAi non-FGR and PI-FGR pregnancies, uterine blood flow was significantly reduced ( ≤ 0.05), while umbilical blood flow ( ≤ 0.01), both uterine and umbilical glucose and oxygen uptakes ( ≤ 0.05), and umbilical concentrations of insulin and IGF1 ( ≤ 0.05) were reduced in CSH RNAi PI-FGR pregnancies. Fetal cotyledon mRNA concentration was reduced ( ≤ 0.05) in CSH RNAi PI-FGR pregnancies, whereas neither nor mRNA concentrations were impacted in the maternal caruncles, and either placental tissue in the non-FGR pregnancies. Fetal cotyledon and mRNA concentrations were not impacted for either phenotype, yet was increased ( ≤ 0.01) in the maternal caruncles of CSH RNAi PI-FGR pregnancies. For the IGF binding proteins (IGFBP1, IGFBP2, IGFBP3), only mRNA concentrations were impacted, with elevated mRNA in both the fetal cotyledon ( ≤ 0.01) and maternal caruncle ( = 0.08) of CSH RNAi non-FGR pregnancies. These data support the importance of IGF1 in placental growth and function but may also implicate IGFBP2 in salvaging placental growth in non-FGR pregnancies. - Source: PubMed
Publication date: 2023/05/26
Hord Taylor KTanner Amelia RKennedy Victoria CLynch Cameron SWinger Quinton ARozance Paul JAnthony Russell V